Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
208 0 |
SM ISO690:2012 VERSPORTEN, Ann P.R., BOLOKHOVETS, Ganna, GHAZARYAN , Lilit, CARP, Angela, NOI, Autori. Antibiotic use in eastern Europe: A cross-national database study in coordination with the WHO Regional Office for Europe. In: The Lancet Infectious Diseases, 2014, vol. 14, pp. 381-387. ISSN 1473-3099. DOI: https://doi.org/10.1016/S1473-3099(14)70071-4 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
The Lancet Infectious Diseases | |
Volumul 14 / 2014 / ISSN 1473-3099 /ISSNe 1474-4457 | |
|
|
DOI:https://doi.org/10.1016/S1473-3099(14)70071-4 | |
Pag. 381-387 | |
Rezumat | |
Background: There are no reliable data on antibiotic use in non-European Union (EU) southern and eastern European countries and newly independent states. We aimed to collect valid, representative, comparable data on systemic antimicrobial use in these non-EU countries of the WHO European region. Methods: Validated 2011 total national wholesale antibiotic-use data of six southern and eastern European countries and regions and seven newly independent states were analysed in accordance with the WHO anatomical therapeutic chemical (ATC)/defined daily doses (DDD) method and expressed in DDD/1000 inhabitants per day (DID). Findings: Total (outpatients and hospital care) antibiotic use ranged from 15·3 DID for Armenia to 42·3 DID for Turkey. Co-amoxiclav was mainly used in Georgia (42·9% of total antibiotic use) and Turkey (30·7%). Newly independent states used substantial quantities of ampicillin and amoxicillin (up to 55·9% of total antibiotic use in Azerbaijan). Montenegro and Serbia were the highest consumers of macrolides (15·8% and 19·5% of total antibiotic use, respectively), mainly azithromycin. Parenteral antibiotic treatment is common practice: 46·4% of total antibiotic use in Azerbaijan (mainly ampicillin; 5·3 DID) and 31·1% of total antibiotic use in Tajikistan (mainly ceftriaxone 4·7 DID). Interpretation: This study provides publicly available total antibiotic-use data for 13 non-EU countries and areas of the WHO European region. These data will raise awareness of inappropriate antibiotic use and stimulate policy makers to develop action plans. The established surveillance system provides a method to develop quality indicators of antibiotic use and to assess the effect of policy and regulatory actions. Funding: Netherlands Ministry of Health, Welfare, and Sport, and EU. |
|
Cuvinte-cheie MeSH Anti-Bacterial Agents, databases, Factual, Drug Utilization, Europe, Eastern, European Union, Humans, World Health Organization |
|
|